Form 4: Madrigal Pharmaceuticals Director Receives Stock Grant

Richard S. Levy, a Director at Madrigal Pharmaceuticals, Inc., was granted restricted stock units and stock options on June 17, 2026.

Summary

• Richard S. Levy, a Director at Madrigal Pharmaceuticals, Inc. (MDGL), received a grant of 454 shares of common stock on June 17, 2026, valued at $0.
• Additionally, Mr. Levy was granted a stock option to purchase 766 shares of common stock with an exercise price of $499.86, expiring on June 17, 2036.
• Both the restricted stock units and the stock option vest on the earlier of June 17, 2027, or the Issuer's annual meeting of stockholders in 2027, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine grant of equity compensation to a director, which is standard practice and does not inherently signal positive or negative company performance.

Positives

• Director Richard S. Levy received a grant of restricted stock units and stock options, indicating continued investment in the company's future by management.
• The stock option has a significant exercise price of $499.86, suggesting it was granted at or above the market price at the time, aligning with executive compensation best practices.
• Vesting is tied to continued service and a future date, incentivizing long-term commitment from the director.

Negatives

• The reported value of the restricted stock units is $0, which may indicate they were granted at a nominal value or that the filing does not reflect the current market value.
• The exercise price of the stock option is high ($499.86), which could make it less likely to be exercised if the stock price does not appreciate significantly.

Risks

• The vesting of both the restricted stock units and stock options is contingent on the reporting person continuing in service with the Issuer, implying a risk of forfeiture if service is terminated before the vesting date.
• The stock option's exercise price of $499.86 presents a risk that it may not become profitable for the holder if the stock price does not exceed this level by the expiration date.

Future Outlook

The future outlook for the granted stock options and restricted stock units is dependent on the continued service of Director Richard S. Levy and the future performance of Madrigal Pharmaceuticals' stock price, with vesting occurring by June 17, 2027, or the 2027 annual meeting.

Industry Context

StockSavvy.ai notes that the issuance of stock options and restricted stock units to directors is a common practice in the biopharmaceutical industry to align executive interests with shareholder value and incentivize long-term performance.

Stakeholder Impact

• Shareholders: The grants align director incentives with shareholder interests, potentially leading to decisions that enhance long-term shareholder value.
• Employees: Standard executive compensation practices can contribute to overall employee morale and retention if perceived as fair and performance-driven.
• Management: The grants provide potential financial upside for the director, contingent on continued service and company performance.

Next Steps

• Director Richard S. Levy to continue in service to meet vesting requirements for restricted stock units and stock options.
• Monitoring of Madrigal Pharmaceuticals' stock price to determine the exercise profitability of the stock option.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Executive Compensation, Director, SEC Filing